中文
English
한국어
日本語
Español
Français
Русский
| 카탈로그 번호 | JN060016 |
|---|---|
| 설명 |
Tefibazumab (JN060016) is a research-grade recombinant antibody targeting clfAClumping factor A. Produced in mammalian cells with native-like glycosylation.
Highlights
|
| 종 반응성 | Staphylococcus aureus |
| 응용 분야 | ELISA, Functional assay, Research in vivo |
| 숙주 종 | Human |
| 클론성 | Monoclonal |
| 이소타입 | IgG1-kappa |
| 발현 시스템 | Mammalian cells |
| 타겟 | clfA Clumping factor A |
| 내독소 수준 | < 10 EU/mg |
| 순도 | >95% purity as determined by SDS-PAGE. |
| 정제 | Protein A/G purified from cell culture supernatant. |
| 등록번호 | Q53653, Q2G015, Q5HHM8 |
| 형태 | Liquid |
| 저장 완충액 | 0.01M PBS pH 7.4 데이터시트 인쇄본 또는 로트별 COA에 기재된 구체적인 완충액 정보를 참조하세요. |
| 안정성 및 저장 | Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt. |
| 대체 이름 | Aurexis, 521079-87-8 |
| 배경 | Clumping factor A (clfAClumping factor A) is a ~97 kDa protein. Cell surface-associated protein implicated in virulence. Promotes bacterial attachment exclusively to the gamma-chain of human fibrinogen. Induces formation of bacterial clumps, which diminish the ability of group IIA phospholipase A2 to cause bacterial phospholipid hydrolysis and killing. Significantly decreases macrophage phagocytosis possibly thanks to the clumps, clumped bacteria being too large to be phagocytosed. Dominant factor responsible for human platelet aggregation, which may be an important mechanism for initiating infective endocarditis. |
| 참고사항 | For research use only. Not suitable for clinical or therapeutic use. |
SEC-HPLC detection for Research Grade Tefibazumab.
SDS-PAGE for Research Grade Tefibazumab.
+86-027-65523339
중국 우한시 심둔사로 666번지 C동, 우한, 430206
